PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Lauds LI-COR Biosciences for Developing NIR Fluorescence, One of the Most Remarkable Advancements in the Biomedical Industry - LI-COR Biosciences' strong reinvestment policy in R&D has made it a leading designer and manufacturer of instrument systems for biotechnology and environmental research - LICOR.com / Frost.com
Frost & Sullivan Lauds LI-COR Biosciences for Developing NIR Fluorescence, One of the Most Remarkable Advancements in the Biomedical Industry

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2013/09/18 - LI-COR Biosciences' strong reinvestment policy in R&D has made it a leading designer and manufacturer of instrument systems for biotechnology and environmental research - LICOR.com / Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the in-vivo molecular imaging market, Frost & Sullivan recognizes LI-COR Biosciences with the 2013 North American Frost & Sullivan Award for Technology Leadership for its near-infrared (NIR) fluorescence technologies. LI-COR has joined hands with various institutions and organizations to achieve a smooth interaction among instruments, kits, and reagents providers.

"As NIR can penetrate depths of several centimeters, it improves the sensitivity of images. It also enables labs to eliminate image processing for spectral unmixing, as the NIR wavelength range has low tissue autofluorescence," said Frost & Sullivan Senior Research Analyst Cecilia Van Cauwenberghe. "These natural advantages of NIR make it ideal for early detection of diseases and, eventually, enhancement of therapeutic protocols."

The appropriate targeting agents for NIR optical imaging can be selected based on well-characterization and specificity in the evaluated compounds. LI-COR Biosciences offers a range of ready-to-use IRDye optical probes capable of targeting a variety of diseases. The IRDye 800CW infrared dye, a fluorescent label developed for numerous targeting agents, including peptides, small molecules, antibodies, antibody drugs, Affibody® molecules, and viruses, has been widely adopted and cited in scientific literature. These agents are compatible with most NIR fluorescence imagers.

BrightSite™ agents, another leading optical imaging tool from LI-COR, allow researchers to begin their experiments without developing new imaging probes. BrightSite™ agents are rigorously validated to ensure high purity, affinity, and specificity.

LI-COR also developed its proprietary Pearl® Impulse Imager, which has been optimized for dual-channel NIR optical imaging. This technology, based on laser excitation, can offer visuals of smaller targets at greater depths.

LI-COR's FieldBrite™ Xi optical design is another remarkable imaging technology that provides optimized, saturation-free images in 10 seconds, thus offering ease of use, high performance, and affordable images that can be used by both inexperienced and experienced optical imaging workers. This technology does away with the need for manual exposure adjustments and repeated exposures to ensure repeatability.

The company has diversified both its biotechnology and environmental product lines. Its expertise in visible and IR markers has significantly enhanced several instruments and applications in biological research. Its proprietary technology seamlessly integrates hardware, software, and labeling technologies to help users perform novel research.

"With global presence and leadership, LI-COR Biosciences is committed to delivering novel and innovative solutions in the life sciences and preclinical industry," noted LI-COR Senior Strategic Marketing Manager, Jim Wiley. "LI-COR continues to develop outstanding technology approaches while establishing a solid collaboration network with service providers and developers, with the aim of providing its customers with well-suited solutions."

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing a technology that significantly impacts both the functionality and the customer value of new products and applications. The award lauds the relevance of the innovation to the industry.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About LI-COR Biosciences
Headquartered in Lincoln, Nebraska, and holding international presence through its offices in Germany, UK, and distribution partners in more than 60 countries, LI-COR® Biosciences is providing researchers and life sciences developers with the most innovative solutions in In vivo Molecular Imaging worldwide.

LI-COR Biosciences (licor.com) has been a leader in the design and manufacture of instrument systems for biotechnology and environmental research. LI-COR pioneered the development of infrared fluorescence labeling and detection systems for life science domains, such as protein analysis and DNA sequencing. LI-COR Biosciences’ technology platform offers unique infrared imaging solutions for a variety of applications, including Western blotting, protein arrays, cell-based assays, and In vivo Molecular Imaging. Additionally, LI-COR instruments for photosynthesis, gas analysis, and light measurement are recognized worldwide for setting standards in plant science research and environmental monitoring.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation.

Contact:
D. Doc Chaves, Director of Marketing Communications
P: 402-467-0750 - E: doc.chaves[.]licor.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Lauds LI-COR Biosciences for Developing NIR Fluorescence, One of the Most Remarkable Advancements in the Biomedical Industry

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Mireya Espinoza - Frost.com 
210-247-3870 mireya.espinoza[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)